Advertise | About Us | Contact Us

Article - Issue 64

Two Acts, One Geopolitical Moment

Article - Issue 64

Why Sustainable Biomanufacturing Must Start Earlier in The Process

Article - Issue 64

From Snapshots to Movies

Article - Issue 64

Maximising Patient Engagement in Clinical Trials

Article - Issue 64

The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding

EDITORIAL SECTIONS

Why X-ray Inspection is a Viable Quality Assurance Solution for Pharma Products

Adopting the Power of AI to Drug Development Projects

A tremendous amount of documentation is created throughout the clinical trial lifecycle

Real-world Evidence

Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA

Just in Time Manufacturing Creating more sustainable supply chains

Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine

Challenges and Advantages of Using Artificial Intelligence in Pharma

Many advanced largescale AI initiatives still need to be proved successful in Pharma

Advisory Board

Victor M. Diaz Perez

Brian D Smith

Nigel Cryer FRSC

Quang Bui

Tamara Miller

Imedla Leslie Rillon

Andri Kusandri

Nicoleta Grecu

Alessio Piccoli

Pramod Kashid

Neil J Campbell

Why Do Pharma Construction Projects Need Cost Certainty | Linesight | ISPE Singapore 2026 | Pharma Focus Asia

Associate Director, Project Controls, Linesight
Stephanie Ledwidge is an experienced project controls and cost management professional with expertise across the life sciences and pharmaceutical sectors She currently serves as Associate Director Project Controls at Linesight in Singapore Her experience spans project controls cost engineering project coordination and project delivery with previous roles supporting organisations including CSL Behr...

Articles

Pharma Firms Must Come Together, Ensure Access to Antibiotics in Poor Countries to Take on Superbugs

In an era marked by remarkable medical advancements a disquieting paradox is staring at us While many parts of the world face a growing threat of antimicrobial resistance owing to overuse of antibiotics several low and middle income countries

Research Insights

Systematic Identification of Pan-cancer Single-gene Expression Biomarkers in Drug High-throughput Screens

Precision oncology relies on molecular biomarkers to stratify patients into responders and nonresponders to a given treatment Although gene expression profiles have historically been explored for biomarker discovery

Case Studies

Impact Of Substitution Among Generic Drugs On Persistence And Adherence:a Retrospective Claims Data Case Study

Abstract Once the period of exclusivity on a reference medicine expires it is possible to apply for marketing of a generic version of that medicine By definition a generic product is considered interchangeable with the innovator brand product when it demonstrates the same qualitative and quantitative composition in active substances the same pharmaceutical form and bi...

Techno Trends

Johnson & Johnson Receives Breakthrough Therapy Designation for RYBREVANT FASPRO™ for the Treatment of Advanced Head and Neck Cancer

Johnson Johnson has introduced RYBREVANT FASPRO for the treatment of patients with advanced head and neck squamous cell carcinoma HNSCC

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

Revolutionising Drug Discovery and Development with Artificial Intelligence

Aarti Chitale

13+ years of healthcare and life sciences industry experience in growth consulting and market intelligence. Aarti Chitale has a strong understanding of pharma and biopharma industry especially the Technology enabled Drug Discovery and Development and Contract Pharma services Industry with keen interest in Emerging Business Models and new growth avenues.

A Structured Review on BCRP-Mediated Multidrug Resistance

Nensi Raytthatha

Nensi Raytthatha Research Scholar, Sigma Institute of Pharmacy, Vadodara. She has published more than 5 research and review papers in reputed journals. She has presented more than 10 posters and have attended national and international conferences.

Isha Shah

Isha Shah, Research Scholar, Sigma Institute of Pharmacy, Vadodara. She has published five research and review papers in reputed journals. She has presented more than 10 posters and have attended national and international conferences.

Jigar Vyas

Jigar Vyas has more than 16 years of teaching and research experience. He has guided more than 40 PG students and has published more than 50 research and review papers. He has received of IQAC award for quality, performance in teaching and research.

Nanoemulsion - A Promising Nanocarrier for Dermal Drug Delivery in Psoriasis

Sindhoor S M

Sindhoor S M is currently working as an Assistant Professor in the Department of Pharmaceutics at Sri Adichunchanagiri College of Pharmacy, Mandya, Karnataka. His areas of specialisation include nanotechnology-based drug delivery system, lipid-based formulations, Topical delivery and gastroretentive in situ gel systems. He has published eight papers based on nanotechnology and lipid-based drug delivery system in peer reviewed indexed journals. Presently he is involved in the development of lipid-based delivery systems.

Marina Koland

Marina Koland, is Professor and Head of the Department of Pharmaceutics at the NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangalore. Her area of specialisation in research is mucoadhesive and nanoparticulate drug delivery. She has published 50 research papers in peer reviewed journals, presented papers at 10 National and 3 International Conferences and worked on several Nitte University funded projects. She is currently working on solid lipid nanoparticles and micelles as drug carriers for targeting.

Government Investment in AI Capabilities will Cement Singapore’s Position as a Premier Clinical Trial Location

Edwin Ng

Edwin Ng joined Medidata in 2014 and heads the Life Science industry of Dassault Systemes across the Asia Pacific region. Under his leadership, the company’s regional business recorded significant year-on-year growth and achieved multiple leadership awards. Edwin has spent the last 27 years of his career managing enterprise solutions businesses.

Why You Might Need a Remediation Program

No Author

No Author

INDUSTRY UPDATES

press releasesRead more...

Sanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®

Sanofi has partnered with NBA Champion KarlAnthony Towns to help raise awareness about the importance of COVID vaccination among those eligible during the respiratory season

ALK expands strategic tablet supply partnership with Catalent

ALK ALKBDC Nasdaq Copenhagen ALK B today announced that it has expanded its longstanding contract manufacturing partnership with Catalent Inc Catalent a leader in enabling the development

Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month

Piramal Pharma Solutions PPS a leading global Contract Development and Manufacturing Organization CDMO and part of Piramal Pharma Ltd PPL NSE PPLPHARMA BSE

OnDosis and Adare Pharma Solutions Announce Strategic Collaboration to Advance OnDosis's Lead U.S. ADHD Program

OnDosis AB OnDosis a Swedish life science company developing drug device combinations for precision dosing of oral solid medicines based on the Dosage Manager device platform and Adare Pharma

Expert Shares Why ADC Development is Demanding a New Level of Bioconjugation Expertise

Antibodydrug conjugates have moved from a promising concept to one of the most actively developed drug classes in oncology Behind that progress lies a manufacturing challenge that is becoming more demanding by the year

Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596

Hengrui Pharma SH HK today announced that it has entered into a license agreement with Novo Nordisk Novo for HRS a phase Iready glucagonlike peptide receptor GLPR